Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
The EU's CHMP has granted a positive opinion for Novartis' combo of MEK inhibitor Mekinist and BRAF inhibitor Tafinlar for BRAF-positive non-small cell lung cancer patients.
UCB says its early to mid-stage pipeline contains 10 promising breakthrough molecules, some of which it aims to partner with other pharma players as part of its open innovation strategy.
Instead of helping raise a Series A, the Teva chairman and others acquire the preclinical company, convinced of its synthetic nanotech promise in immuno-oncology. Vifor and ChemoCentryx expand their orphan and renal disease collaboration, while Gilead out-licenses an addiction drug candidate.
Celltrion's version of Roche’s MabThera (rituximab), Truxima, has become the first biosimilar anticancer to win marketing authorization in Europe.
Hopes for wider use of AstraZeneca Lynparza (olaparib) were boosted by Phase III data showing improved survival rates in patients with a certain type of breast cancer who used the PARP inhibitor compared with chemotherapy alone.
The US patent office's initial ruling on CRISPR patents that granted the Broad Institute a victory at the expense of the University of California caps the first major skirmish in what will be a long, drawn-out corporate legal battle.